Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations.

Pugliatti, Maura; Berger, Thomas; Hartung, Hans-Peter; Oreja-Guevara, Celia; Bar-Or, Amit

Pugliatti, Maura; Berger, Thomas; Hartung, Hans-Peter; Oreja-Guevara, Celia; Bar-Or, Amit.

Afiliação

Pugliatti M; Department of Neuroscience and Rehabilitation, University of Ferrara.
Berger T; Department of Neuroscience and Rehabilitation, S. Anna University Hospital, Ferrara.
Hartung HP; Interdepartmental Research Center on Multiple Sclerosis and other neuroinflammatory and -degenerative diseases, University of Ferrara, Italy.
Oreja-Guevara C; Department of Neurology, Medical University of Vienna, Vienna, Austria.
Bar-Or A; Department of Neurology, Universitätsklinikum Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.

Curr Opin Neurol ; 35(3): 319-327, 2022 06 01.

Article em En | MEDLINE | ID: mdl-35674075

Assuntos

COVID-19; Esclerose Múltipla; COVID-19/prevenção & controle; Vacinas contra COVID-19/uso terapêutico; Progressão da Doença; Humanos; Masculino; Esclerose Múltipla/epidemiologia; RNA Viral; SARS-CoV-2; Vacinação; Adulto Jovem

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Esclerose Múltipla Tipo de estudo: Prognostic_studies Limite: Adult / Humans / Male Idioma: En Revista: Curr Opin Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google